71886-83-4

Basic information

• Product Name: 6-methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one
• Synonyms: 6-methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one;3,4-dihydro-6-methoxy-1,1-dimethylnaphthalen-2(1H)-one
• CAS NO: 71886-83-4
• Molecular Formula: C₁₃H₁₆O₂
• Molecular Weight: 204.26494
• Mol File: 71886-83-4.mol

Chemical Properties

• Boiling Point: 108-113 °C(Press: 0.5-0.6 Torr)
• Appearance: /
• Density: 1.046±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 6-methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one(71886-83-4)
• EPA Substance Registry System: 6-methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one(71886-83-4)

Safety Data

• Hazardous Substances Data: 71886-83-4(Hazardous Substances Data)

Upstream product

• 2472-22-2 6-methoxy-2-tetralone 
• 74-88-4 methyl iodide 
• 581-43-1 2.6-dihydroxynaphthalene 
• 5486-55-5 2,6-dimethoxylnaphthalene 
• 65472-33-5 3,7-dimethoxy-1,2-dihydro-naphthalene 
• 135-76-2 sodium 2-naphthol-6-sulfonate 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 
• 4242-13-1 7-methoxy-4-methyl-1,2-dihydronaphthalene 
• 5111-67-1 1-methyl-6-methoxy-2-tetralone 

Downstream Products

• 95946-45-5 1,2,3,4,5,8-Hexahydro-6-methoxy-2-<4-methoxy-1,4-cyclohexadien-(1)-yl>-1,1-dimethyl-naphthalin 
• 95556-55-1 1,4-Dihydro-6-methoxy-2-(p-methoxy-phenyl)-1,1-dimethyl-naphthalin 
• 110247-14-8 6-(4-phenyl-semicarbazono)-1.1-dimethyl-1.2.3.4.6.7.8.8a-octahydro-naphthalene 
• 71886-95-8 trans-1,2,3,4,4a,5,6,8a-octahydro-1,1-dimethyl-4a-(tosyloxymethyl)-6α-tris(methylthio)methylnaphthalen-6β-ol 
• 71886-97-0 methyl trans-1,2,3,4,4a,5,6,8a-octahydro-1,1-dimethyl-6β-hydroxy-4a-(tosyloxymethyl)naphthalene-6-carboxylate 
• 71886-94-7 trans-1,2,3,4,4a,5,6,8a-octahydro-1,1-dimethyl-6,6-ethylenedioxy-4a-(tosyloxymethyl)naphthalene 
• 71887-05-3 trans-5,5-dimethyl-2,2-ethylenedioxy-8a-(tosyloxymethyl)decahydronaphthalene 
• 71887-06-4 trans-octahydro-5,5-dimethyl-8a-tosyloxymethyl-2(1H)-naphthalenone 
• 71901-44-5 trans-4a,5,6,7,8,8a-hexahydro-5,5-dimethyl-8a-(tosyloxymethyl)-2(1H)-naphthalenone 
• 71887-21-3 methyl 5,5-dimethyl-3-hydroxy-11-oxa-2-oxotricyclo<7.2.1.0^4,9>dodec-3-ne-1α-carboxylate 
• 96168-79-5 1,2,3,4-Tetrahydro-2-hydroxy-6-methoxy-2-(4-methoxy-m-tolyl)-1,1-dimethyl-naphthalin 

Relevant articles and documents

Ring-expansion approaches for the total synthesis of salimabromide

We describe the evolution of a synthetic strategy for the construction of the marine polyketide salimabromide. Combining a bicyclo[3.1.0]hexan-2-one ring-expansion to build up a functionalized naphthalene and an unprecedented rearrangement/cyclization cascade, enabled synthesis of a dearomatized tricyclic subunit of the target compound. Alternatively, an intramolecular keteniminium [2 + 2]-cycloaddition and subsequent Baeyer–Villiger ring-expansion gave access to the sterically encumbered architecture of salimabromide. Sequential oxidation of the carbon framework finally enabled the total synthesis of this unusual natural product.

4-(2-AMINO-TETRAHYDRONAPHTHALENYL)PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies

A series of novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety were synthesized and evaluated for their anti-anaplastic lymphoma kinase (ALK) activities using enzymatic and cell-based assays. Among the compounds synthesized, compound 17b showed promising pharmacological results in in vitro, ex vivo, and pharmacokinetic studies. An in vivo efficacy study with compound 17b demonstrated highly potent inhibitory activity in H3122 tumor xenograft model mice. A series of kinase assays showed that compound 17b inhibited various kinases including FAK, ACK1, FGFR, RSK1, IGF-1R, among others, thus demonstrating its potential for synergistic anti-tumor activity and development as a multi-targeted non-small cell lung cancer (NSCLC) therapy.

COMPOSITION COMPRISING TETRACYCLIC COMPOUND

A composition which comprises substance represented by Formula (I), [Meanings of the symbols that are included in the formula are given in the specification as definitions] a pharmaceutically acceptable carrier, and a dissolution aid. is useful for improving solubility, oral absorbability and/or absorbability in blood of a poorly water-soluble or water insoluble tetracyclic compounds having an ALK inhibitory activity that are useful as a prophylactic and/or therapeutic agent for cancer, depression, and cognitive function disorder.

Synthesis of a Model for the BCE Ring System of Bruceantin. A Caveat on the Cyclohexene -> Trans Diaxial Diol Conversion

A BCE ring model (2) of the quassinoidal antileukemia agent bruceantin (1) has been prepared.The key features of the synthesis include formation of the tetrahydrofuran 19 (or 21) from the tosyloxy enone 17 through alcohol tosylate 18 (or 20) via intramolecular solvolytic ring closure; direct cyclization to 19 under basic conditions failed due to the unfavorable geometric constraints imposed by the olefinic moiety of 17.Tosyloxy ketone 31, a saturated version of 17, smoothly cyclized under basic conditions.Attempts to introduce the requiste trans diol functionality from tricyclic 21 by epoxide opening or Prevost reactions were completely unsuccessful; numerous examples of the intervention of the tetrahydrofuran oxygen were documented.The olefin -> trans diol conversion was eventually achieved in high overall yield by a three-step procedure: (i) cis hydroxylation of 21 to 52; (ii) regiospecific oxidation of 52 to ketol 53 via an intramolecular, tetrahydrofuran-assisted, decomposition of a sulfoxonium ion under nonbasic conditions; followed by (iii) stereospecific reduction of 53 to trans diol 2. 13C NMR correlation was made between trans diol 2 and its mono- and diacetate derivatives with natural bruceantin 1 and its derivatives.Cytological evaluation showed trans diol 2 to be inactive in the KB system.